Tert-butyl 3-(methylamino)azepane-1-carboxylate | 484638-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: Tert-butyl 3-(methylamino)azepane-1-carboxylate
• CAS: 484638-83-7
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.33
• InChiKey: BLSRUKYVCUYXKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel Cyclic Amino Benzoic Acid Derivative
  申请人：Nomura Masahiro

  公开号：US20070249580A1

  公开（公告）日：2007-10-25

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C 1 -C 4 alkylene, C 2 -C 4 alkenylene, C 2 -C 4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH 2 ) n — (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and —COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及循环氨基苯甲酸衍生物，作为人类过氧化物酶体增殖物激活受体（PPAR）激动剂，在治疗脂质代谢异常、糖尿病等方面具有有效性，特别是作为人类PPARα亚型的激动剂，以及其加成盐和含有这些化合物的药物组合物。其中，循环氨基苯甲酸衍生物的一般式（1）表示为[其中，环Ar表示可能具有取代基的芳基；Y表示C1-C4烷基、C2-C4烯基、C2-C4炔基或类似物；Z表示氧原子、硫原子或—（CH2）n—（n表示0、1或2）；X表示氢原子、卤原子、可能带有卤原子取代的低烷基或类似物；R表示氢原子或低烷基，而—COOR代替环W的结合位置的邻位或间位]或其药学上可接受的盐。
• NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP1780210A1

  公开（公告）日：2007-05-02

  The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.

  本发明涉及作为人过氧化物酶体增殖激活受体（PPAR）激动剂，特别是作为人PPARα同工酶的激动剂，对脂质代谢异常、糖尿病等治疗有效的环氨基苯甲酸衍生物及其加成盐，以及含有这些化合物的药物组合物。 由通式（1）代表的环氨基苯甲酸衍生物 [其中，环 Ar 代表芳基，可具有取代基等；Y 代表 C1-C4 亚烷基、C2-C4 亚烯基、C2-C4 亚炔基等；Z 代表氧原子、硫原子或 - (CH2)n- （n 代表 0、1 或 2）；X 代表氢原子、卤素原子、可被卤素原子取代的低级烷基或类似物；R 代表氢原子或低级烷基，-COOR 取代环 W 结合位的正位或甲位]或其药学上可接受的盐。
• 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3689871A1

  公开（公告）日：2020-08-05

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

  本公开涉及4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及其制剂和药用。具体地说，本公开公开了式(I)化合物或其药学上可接受的盐、立体异构体、溶媒或原药及其制备方法和用途，其中各组的定义如说明书和权利要求书中所述。
• 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US11155546B2

  公开（公告）日：2021-10-26

  The present disclosure relates to 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives, and their preparations and medicinal use. Specifically, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof, wherein the definition of each group is as described in the specification and claims.

  本公开涉及4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及其制剂和药用。具体地说，本公开公开了式(I)化合物或其药学上可接受的盐、立体异构体、溶媒或原药及其制备方法和用途，其中各组的定义如说明书和权利要求书中所述。
• Derivatives of oxazolidinones as antibacterial agents
  申请人：——

  公开号：US20040147545A1

  公开（公告）日：2004-07-29

  This invention discloses new fluorquinolonic derivatives of oxazolidinones of general formula (I) and processes for obtaining them, the corresponding pharmaceutical compositions and use thereof for manufacturing a medicament for the treatment of microbial infections. These new compounds are useful as antibacterial agents. Formula (I). Furthermore phenalen-type compounds according to general formula (II) are disclosed. Formula (II).

  本发明公开了通式(I)的噁唑烷酮的新氟喹诺酮衍生物、获得它们的工艺、相应的药物组合物及其用于制造治疗微生物感染的药物。这些新化合物可用作抗菌剂。式 (I)。此外，还公开了通式（II）的苯茚类化合物。式 (II).